4d Pharma : Director/PDMR Shareholding

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

4D pharma plc

(the 'Company' or '4D')

PDMR Dealings

4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, is pleased to announce that David Norwood has purchased ordinary shares in the Company as listed below. Following this transaction, Mr Norwood has a resulting interest in the ordinary shares of the Company as listed below.

Name		Shares in 4D pharma plc before purchase	% of total shares in issue	Shares in 4D pharma plc after purchase	% of total shares in issue
David Norwood (Chairman)		7,070,000	10.79%	7,080,000	10.81%

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	David Norwood
2	Reason for the notification
a)	Position/status	PDMR
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	4D Pharma plc
b)	LEI	213800O49VYSXWE2ZD52
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary shares of £0.0025 ISIN: GB00BJL5BR07
b)	Nature of the transaction	Purchase of Ordinary Shares
c)	Price(s) and volume(s)	Price(s) Volume(s) 103p 10,000
d)	Aggregated information - Aggregated volume - Price	N/A
e)	Date of the transaction	20th December 2018
f)	Place of the transaction	London Stock Exchange, AIM

For further information please contact:

4D
Duncan Peyton, Chief Executive Officer Fay Weston, Head of Investor Relations	+ 44 (0)113 895 0130 + 44 (0)7990 381713
Zeus Capital Limited - Nomad and Joint Broker	[phone]
Dan Bate / Jordan Warburton
Bryan Garnier & Co. Limited - Joint Broker	[phone]
Dominic Wilson Phil Walker